On November 5, McKesson rose 3.35% in Regular Trading, trading at $1094.96/share, with turnover of $102 million.
The clearest catalyst was the company’s latest quarterly report and raised guidance, followed later by an analyst price-target increase.
McKesson reported fiscal Q2 adjusted EPS of $11.68, up from $9.86 a year earlier and above the $10.72 consensus, while revenue rose to $110.96 billion from $103.15 billion and exceeded the $109.90 billion expectation. The company also lifted its fiscal 2027 adjusted EPS outlook to $45.60-$46.40 from $44.20-$45.00, ahead of the $44.65 market view. Separately, Leerink Partners raised its price target to $1,200 from $1,070, above the broader analyst mean target of about $1,122.71. These updates reinforced positive sentiment after recent expansion moves, including the pending Option Care Health transaction.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments